Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA President Ross Muken completed an open-market sale of 2,800 Ordinary Shares at a weighted average price of $4.9597 per share. After this transaction, he directly holds 682,432 shares. The sale was made to cover tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026 and was executed under a pre-established Rule 10b5-1(c) trading plan, meaning it did not represent a discretionary trade.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported selling 2,400 Ordinary Shares of SOPH on April 10, 2026 at a weighted average price of $4.6672 per share. The footnotes state these shares were sold in the open market solely to satisfy tax withholding obligations from restricted stock units vesting on April 2 and 3, 2026.
The sales were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. After the transaction, Van Well directly holds 346,420 Ordinary Shares, indicating he retained a substantial equity position in the company.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported open‑market sales of 8,120 Ordinary Shares of SOPH. The shares were sold on April 10 and April 13, 2026 at weighted average prices around $4.68–$4.76 per share.
According to the disclosure, these sales were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026, and were carried out under a pre‑established Rule 10b5‑1(c) trading plan. Following the transactions, Xu continues to hold 632,096 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported open-market sales of 16,631 ordinary shares of SOPH. The shares were sold on April 10 and 13, 2026 at weighted average prices around $4.72–$4.76 per share.
Footnotes state these transactions were effected under a pre-established Rule 10b5-1(c) trading plan to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, and are not discretionary trades. After these sales, Camblong continues to hold 3,707,569 ordinary shares directly.
SOPHiA GENETICS SA President Ross Muken reported two small open-market sales of Ordinary Shares to cover taxes from equity vesting. On April 10 and 13, 2026, he sold a total of 8,129 shares at weighted average prices around $4.69–$4.77 per share. A footnote explains these transactions were made to satisfy tax withholding obligations arising from restricted stock units that vested on April 2 and 3, 2026, and were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. Following the sales, he continues to hold 685,232 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported small open-market sales of Ordinary Shares mainly to cover taxes from recent equity vesting. Across three transactions on April 10 and April 13, 2026, he sold a total of 8,125 shares at weighted-average prices around $4.68–$4.76 per share. The filing states these sales were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1(c) trading plan. After these transactions, Menu continues to hold 268,596 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported routine tax-related share sales. He sold 2,800 Ordinary Shares on April 8 at a weighted average of $4.8404 and 1,950 shares on April 9 at a weighted average of $4.7404 in open‑market transactions.
Footnotes state these sales were made solely to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026, under a pre‑established Rule 10b5‑1 trading plan. After these transactions, he continues to hold 3,724,200 Ordinary Shares directly.
SOPHiA GENETICS SA president Ross Muken reported open-market sales of ordinary shares primarily to cover taxes from equity compensation. On April 8 and 9, 2026, he sold a total of 4,736 shares at weighted average prices of about $4.84 and $4.74 per share. The filing states these trades were executed under a pre-established Rule 10b5-1 trading plan and were made to satisfy tax withholding obligations tied to restricted stock units that vested earlier in April. After these sales, Muken still directly holds 693,361 ordinary shares, indicating the transactions represent a small portion of his overall position.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 4,736 Ordinary Shares of SOPH in open-market transactions. The sales occurred on April 8 and 9, 2026 at weighted average prices of about $4.84 and $4.74 per share.
According to the disclosure, these shares were sold to cover tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. The transactions were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After the sales, Xu directly held 640,216 Ordinary Shares.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu disposed of 4,731 Ordinary Shares in open-market sales tied to tax obligations. On April 8, he sold 2,800 shares at a weighted average of $4.8370, and on April 9 he sold 1,931 shares at a weighted average of $4.7393.
The footnotes state these sales were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1 trading plan, meaning they were not discretionary trades. After these transactions, Menu directly holds 276,721 Ordinary Shares.